Skip to content
drillr.ai
Sign up

VRTX

VERTEX PHARMACEUTICALS INC / MA

NASDAQ · Healthcare · Biotechnology · US

$549.04
+3.44%
Ask drillr

  • Nov 4, 2026, 11:22 UTC

    VERTEX PHARMACEUTICALS INC / MA reported that Q3 fiscal 2027 revenue rose 12% year over year to $3.44 billion, driven by cystic fibrosis and newer products CASGEVY and PALSONIFY.

    Source:

  • Nov 3, 2026, 16:06 UTC

    VERTEX PHARMACEUTICALS INC / MA raised its 2026 sales outlook.

    Source:

  • Nov 2, 2026, 23:25 UTC

    VERTEX PHARMACEUTICALS INC / MA reported quarterly earnings of $4.76 per share, below the Zacks Investment Research, Inc. Consensus Estimate of $4.92 and compared with $4.80 per share a year earlier.

    Source:

  • Nov 2, 2026, 21:31 UTC

    VERTEX PHARMACEUTICALS INC / MA reported Q3 2026 revenue of $3.44 billion, up 12% year over year, and net income of $654 million.

    Source:

  • Oct 23, 2026, 17:42 UTC

    VERTEX PHARMACEUTICALS INC / MA announced publication of Phase 3 RAINIER results for povetacicept in IgA nephropathy in the New England Journal of Medicine and presentation of the data at ASN Kidney Week 2026.

    Source:

  • Oct 20, 2026, 22:51 UTC

    VERTEX PHARMACEUTICALS INC / MA shares closed at $514.70, up 2.54% from the prior trading day.

    Source:

  • Oct 15, 2026, 23:00 UTC

    VERTEX PHARMACEUTICALS INC / MA shares closed at $508.75, up 2.06% from the previous close.

    Source:

  • Oct 9, 2026, 22:51 UTC

    VERTEX PHARMACEUTICALS INC / MA shares closed at $510.08, up 1.36% from the previous trading day.

    Source:

  • Oct 1, 2026, 23:00 UTC

    Vertex Pharmaceuticals (VRTX) shares closed at $506.74, down 3.07% from the previous trading session.

    Source:

  • Sep 22, 2026, 17:55 UTC

    Vertex Pharmaceuticals reported Phase 2b AMPLIFIED trial data showing inaxaplin reduced proteinuria in patients with APOL1-mediated kidney disease.

    Source:

  • Sep 18, 2026, 17:20 UTC

    Vertex Pharmaceuticals raised its full-year revenue guidance to $13.1 billion to $13.2 billion from a previous range of $12.95 billion to $13.1 billion.

    Source:

  • Sep 18, 2026, 17:20 UTC

    Vertex Pharmaceuticals reported second-quarter results with revenue up 12% year over year to $3.33 billion and earnings per share up 8% year over year to $4.31.

    Source:

  • Sep 14, 2026, 23:45 UTC

    The U.S. Court of Appeals for the D.C. Circuit ruled in Vertex Pharmaceuticals Inc. v. U.S. Department of Health and Human Services, broadly construing the Anti-Kickback Statute, reversing OIG's finding that Vertex's Fertility Support Program violated the Beneficiary Inducement Statute, and striking down OIG's advisory opinion timing regulations.

    Source:

  • Sep 1, 2026, 20:28 UTC

    Vertex Pharmaceuticals announced that Jonathan Poole will become Executive Vice President and Chief Financial Officer, effective January 1, 2027, succeeding Charles F. Wagner, Jr., who will transition to Executive Vice President and Chief Operating & Financial Officer.

  • Aug 23, 2026, 09:03 UTC

    EP Wealth Advisors LLC acquired a new stake in Vertex Pharmaceuticals Incorporated during the second quarter, purchasing 9,027 shares valued at approximately $4,484,000.

    Source:

  • Aug 20, 2026, 07:18 UTC

    AssuredPartners Investment Advisors LLC acquired a new stake in Vertex Pharmaceuticals Incorporated, purchasing 4,147 shares valued at approximately $2.06 million, as disclosed in a recent SEC filing.

    Source:

  • Aug 10, 2026, 12:03 UTC

    Sionna Therapeutics announced that its experimental cystic fibrosis pill SION-719 failed to show benefit in a Phase 2 trial when added to Vertex Pharmaceuticals' Trikafta, and the company will not advance it as an add-on therapy.

    Source:

  • Jul 29, 2026, 21:00 UTC

    Latigo Biotherapeutics published positive Phase 2 trial data for its experimental pain drug LTG-001, a potential rival to Vertex's Journavx, on July 29, 2026.

    Source:

  • Jul 29, 2026, 11:00 UTC

    AbCellera announced a collaboration with Vertex to discover multispecific T-cell engagers for autoimmune diseases and other conditions.

    Source:

  • Jul 7, 2026, 00:00 UTC

    Vertex Pharmaceuticals signed a merger agreement to acquire Crinetics Pharmaceuticals for $85.00 per share in cash, expected to close in Q3 2026.

    Source:

  • Jul 2, 2026, 15:46 UTC

    Vertex Pharmaceuticals received FDA approval to expand the use of Casgevy in patients aged two and older with sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT).

    Source:

  • Jun 3, 2026, 12:00 UTC

    The FDA granted 510(k) clearance for the BD BACTEC FXI Culture System, a bloodstream infection diagnostic device.

    Source:

  • Jun 2, 2026, 16:51 UTC

    NeuroPace (NPCE) received FDA approval for its AI-powered ECoG Assistant for epilepsy.

    Source:

  • Jun 2, 2026, 16:10 UTC

    The FDA accepted Vertex's Biologics License Application for povetacicept in adults with IgA nephropathy, with a decision due in November 2026.

    Source: